Stryker (SYK) Sees Higher Price Target from UBS amid Continued MedTech Strength
During the Q4 2025 earnings call, CEO Kevin Lobo described 2025 as an outstanding year. He said both the fourth quarter and the full year delivered strong results across key financial measures.






